Delcath Systems, Inc. — Q3 2014 Form 10-Q Summary
Business Context and Reporting Period
Delcath is an oncology specialty pharmaceutical and medical-device company developing Melphalan/Hepatic Delivery System (Melphalan/HDS), marketed in Europe as CHEMOSAT for liver cancers. CHEMOSAT has CE Mark authorization and is sold in Europe; Melphalan/HDS had not been approved for sale in the United States as of September 30, 2014. The filing covers the three and nine months ended September 30, 2014, compared with the corresponding 2013 periods.
Financial Performance and Position
| Metric | Q3 2014 | Q3 2013 | 9M 2014 | 9M 2013 |
|---|---|---|---|---|
| Total revenue | $0.2 million | $0.1 million | $0.8 million | $0.5 million |
| Gross profit | $0.2 million | $0.05 million | $0.6 million | $0.1 million |
| Approximate gross margin | 77% | 68% | 73% | 15% |
| Operating loss | $5.1 million | $6.7 million | $16.0 million | $27.5 million |
| Net loss | $4.6 million | $7.2 million | $14.4 million | $25.5 million |
| Loss per share | $0.48 | $1.15 | $1.54 | $4.35 |
| Cash used in operations | Not separately provided | Not separately provided | $12.4 million | $28.9 million |
Cash and cash equivalents were $23.3 million at September 30, 2014, down from $31.2 million at December 31, 2013. Total current assets were $24.8 million versus $34.0 million at year-end 2013, while current liabilities were $5.1 million versus $6.6 million. The filing does not report conventional funded debt; liabilities included a $0.6 million warrant liability and $1.1 million of other non-current liabilities. Stockholders’ equity was $20.7 million.
Operating cash usage improved by $16.5 million year over year, principally because of lower NDA-related costs and reduced operating expenses. Financing activities provided $4.5 million, primarily from stock sales and warrant exercises. The company reported no significant capital expenditures during the nine months.
Material Changes Versus the Prior Comparable Period
- Product revenue increased to $0.8 million for the first nine months from $0.2 million in product revenue in the prior-year period; the 2013 period also included $0.3 million of other deferred revenue.
- Q3 net loss decreased 36.1% to $4.6 million; nine-month net loss decreased 43.5% to $14.4 million.
- Nine-month selling, general and administrative expense declined to $13.0 million from $16.9 million, and research and development expense declined to $3.6 million from $10.6 million.
- Restructuring charges remained material: approximately $1.4 million in Q3 and $2.3 million year to date, including workforce reductions and office lease restructuring. The remaining restructuring reserve was approximately $1.4 million at September 30, 2014.
- Derivative warrant income was $0.5 million in Q3 and $1.6 million year to date, versus a Q3 expense of $0.5 million and nine-month income of $2.3 million in 2013. This was a non-cash fair-value adjustment.
- CHEMOSAT treatments performed in Europe increased to 59 during the first nine months from 27 in the prior-year period, including 25 retreatments versus eight.
- The company completed a one-for-sixteen reverse stock split on April 8, 2014. Approximately 1.0 million shares were sold under the ATM program during the first quarter for net proceeds of approximately $4.4 million.
Guidance, Outlook, Risks and Unusual Items
Management stated that existing capital resources were adequate to fund operations through the next twelve months, but additional working capital would be required to continue operations. Because the company has never generated positive operating cash flow, management expects to seek additional financing through equity, debt or strategic relationships. Failure to obtain capital could force abandonment or reduction of clinical development and commercialization efforts.
- Management planned a global Phase 3 ocular melanoma liver-metastasis trial, targeting initiation in mid-2015, subject to regulatory and operational readiness.
- Phase 2 HCC trials were open in Europe and the United States, with an ICC cohort planned. Initial data from the first eleven patients were anticipated in the first half of 2015, subject to enrollment.
- U.S. approval remained uncertain. The FDA issued a Complete Response Letter in September 2013 requiring another well-controlled randomized trial using overall survival as the primary endpoint.
- European commercialization remained dependent on reimbursement, particularly in Germany and the United Kingdom. UK funding through the Commissioning Through Evaluation process was delayed and remained difficult to predict.
- The company disclosed significant treatment risks, including potentially life-threatening adverse reactions, severe bone marrow suppression, stroke, myocardial infarction, hepatic injury, hemorrhage and gastrointestinal perforation. Management believes product and procedural refinements may improve safety, but formal controlled-trial evidence remained necessary.
- Material legal proceedings included securities litigation and derivative shareholder litigation related primarily to disclosures concerning the U.S. NDA and manufacturing facilities. The company disputed the claims and intended to defend them vigorously.
- Management leadership changed in September 2014: Jennifer Simpson became interim President and CEO, Graham Miao departed, Barbra Keck assumed principal financial officer responsibilities, and Roger Stoll became Executive Chairman.
- After quarter-end through November 4, 2014, the company sold approximately 0.3 million additional shares under its ATM program for net proceeds of approximately $0.4 million.
Most Important Facts for Investors to Verify
- Whether $23.3 million of cash is sufficient to fund planned clinical programs and commercialization before additional financing is required.
- The timing, cost, enrollment and regulatory acceptance of the planned ocular melanoma Phase 3 trial and ongoing HCC/ICC Phase 2 programs.
- Progress toward FDA approval following the Complete Response Letter and the evidence required for a successful resubmission.
- Actual European reimbursement outcomes and whether treatment volume converts into sustainable revenue and positive gross margins.
- Potential dilution from the remaining ATM capacity, the approximately $23.9 million available under the CEFF program, outstanding warrants and other equity instruments.
- Exposure from securities and derivative shareholder litigation, including any class-certification developments and potential financial impact.
- The effect of restructuring charges, lease obligations, retention bonuses and warrant fair-value changes on future cash requirements and reported earnings.